基于机器学习的晚期霍奇金淋巴瘤无进展生存期和总生存期预测模型

IF 3.3 Q2 ONCOLOGY
R. Rask Kragh Jørgensen, Fanny Bergström, S. Eloranta, M. Tang Severinsen, K. Bjøro Smeland, Alexander Fosså, J. Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Sørensen, P. Kamper, I. Glimelius, Karin E Smedby, Susan K Parsons, Angie Mae Rodday, Matthew J Maurer, Andrew M Evens, Tarec C El-Galaly, L. Hjort Jakobsen
{"title":"基于机器学习的晚期霍奇金淋巴瘤无进展生存期和总生存期预测模型","authors":"R. Rask Kragh Jørgensen, Fanny Bergström, S. Eloranta, M. Tang Severinsen, K. Bjøro Smeland, Alexander Fosså, J. Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Sørensen, P. Kamper, I. Glimelius, Karin E Smedby, Susan K Parsons, Angie Mae Rodday, Matthew J Maurer, Andrew M Evens, Tarec C El-Galaly, L. Hjort Jakobsen","doi":"10.1200/CCI.23.00255","DOIUrl":null,"url":null,"abstract":"PURPOSE\nPatients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS).\n\n\nPATIENTS AND METHODS\nThis study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort).\n\n\nRESULTS\nIn total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis.\n\n\nCONCLUSION\nThe new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-HIPI.","PeriodicalId":51626,"journal":{"name":"JCO Clinical Cancer Informatics","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma.\",\"authors\":\"R. Rask Kragh Jørgensen, Fanny Bergström, S. Eloranta, M. Tang Severinsen, K. Bjøro Smeland, Alexander Fosså, J. Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Sørensen, P. Kamper, I. Glimelius, Karin E Smedby, Susan K Parsons, Angie Mae Rodday, Matthew J Maurer, Andrew M Evens, Tarec C El-Galaly, L. Hjort Jakobsen\",\"doi\":\"10.1200/CCI.23.00255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PURPOSE\\nPatients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS).\\n\\n\\nPATIENTS AND METHODS\\nThis study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort).\\n\\n\\nRESULTS\\nIn total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis.\\n\\n\\nCONCLUSION\\nThe new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-HIPI.\",\"PeriodicalId\":51626,\"journal\":{\"name\":\"JCO Clinical Cancer Informatics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO Clinical Cancer Informatics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/CCI.23.00255\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Clinical Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/CCI.23.00255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的诊断为晚期霍奇金淋巴瘤(aHL)的患者历来使用国际预后评分(IPS)进行风险分级。本研究调查了机器学习(ML)方法在预测总生存期(OS)和无进展生存期(PFS)方面是否优于现有模型。ML 模型采用堆叠法开发,将多个预测生存模型(Cox 比例危险模型、灵活参数模型、IPS、主成分、惩罚回归)合并为一个模型,并与两个版本的 IPS(IPS-3 和 IPS-7)和新开发的 aHL 国际预后指数(A-HIPI)进行比较。模型内部验证采用嵌套交叉验证法,外部验证采用瑞典淋巴瘤登记处和挪威癌症登记处的患者数据(验证队列)。在对开发队列中的 OS 模型性能进行检查时发现,ML 模型、IPS-7、IPS-3 和 A-HIPI 的一致性指数(C-index)分别为 0.789、0.608、0.650 和 0.768。验证队列中的相应估计值分别为 0.749、0.700、0.663 和 0.741。就 PFS 而言,ML 模型在两个队列中都获得了最高的 C 指数(开发队列为 0.665,验证队列为 0.691)。结论与 IPS 模型相比,基于 ML 技术的 aHL 新预后模型有了很大改进,但与 A-HIPI 相比,其预测性能的改进有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma.
PURPOSE Patients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS). PATIENTS AND METHODS This study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort). RESULTS In total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis. CONCLUSION The new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-HIPI.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
4.80%
发文量
190
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信